학술논문

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Document Type
Journal
Source
BLOOD; NOV 5 2020, 136 4p. Supplement: 1
Subject
Language
English
ISSN
15280020